MARKET

ONC

ONC

BeOne Medicines Ltd.
NASDAQ
362.06
+3.06
+0.85%
Opening 13:29 08/11 EDT
OPEN
360.00
PREV CLOSE
359.00
HIGH
366.97
LOW
360.00
VOLUME
304.85K
TURNOVER
--
52 WEEK HIGH
385.22
52 WEEK LOW
253.95
MARKET CAP
41.17B
P/E (TTM)
63.79
1D
5D
1M
3M
1Y
5Y
1D
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Seeking Alpha · 18h ago
BeOne Medicines (ONC) Is Up 11.0% After Raising 2026 Revenue and Operating Income Guidance – What's Changed
Simply Wall St · 1d ago
BeOne Medicines price target raised to $370 from $340 at Wolfe Research
TipRanks · 1d ago
BeOne Medicines partners with Revolution Medicines for clinical development
TipRanks · 1d ago
BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations Using Select Clinical-Stage Oncology Assets From BeOne With Any Of Revolution’s Four Clinical RAS(ON) Inhibitors
Benzinga · 1d ago
Weekly Report: what happened at ONC last week (0803-0807)?
Weekly Report · 1d ago
BOCOM International Holdings Company Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
TipRanks · 2d ago
BeOne Medicines (ONC) Stock Looks Strong On Returns But Above Fair Value
Simply Wall St · 2d ago
More
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Webull offers BeOne Medicines AG (ADR) stock information, including NASDAQ: ONC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONC stock methods without spending real money on the virtual paper trading platform.